The National Drug Code (NDC) 00169 is associated with Wegovy, a brand-name prescription medication [1]. Wegovy is an injectable medication used for chronic weight management in adults who are obese or overweight and have at least one weight-related condition [1].
What active ingredient is in Wegovy?
Wegovy contains semaglutide as its active ingredient [1]. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist [1].
How does semaglutide work for weight loss?
Semaglutide mimics the action of the GLP-1 hormone, which is naturally released in the body after eating. It helps to increase feelings of fullness and reduce appetite, thereby aiding in weight management [1].
What dosages of Wegovy are available?
Wegovy is available in several dosage strengths, typically administered once weekly via subcutaneous injection. The dosage is usually started low and gradually increased to the maintenance dose [1].
How long does Wegovy treatment typically take to show results?
Patients using Wegovy may see significant weight loss results over time, with continued use and adherence to dosage titration schedules [1].
Can Wegovy be used for diabetes management?
While Wegovy contains semaglutide, which is also the active ingredient in the diabetes medication Ozempic, Wegovy is specifically indicated and approved for chronic weight management [1]. Ozempic is indicated for type 2 diabetes management [1].
What are the common side effects of Wegovy?
Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. These side effects are often dose-dependent and may decrease over time as the body adjusts to the medication [1].
Are there serious risks associated with Wegovy?
Serious risks associated with Wegovy can include pancreatitis, gallbladder problems, kidney issues, severe allergic reactions, and a type of thyroid tumor called medullary thyroid carcinoma (MTC) or thyroid C-cell tumors [1]. Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Wegovy [1].
What is the prescribed way to administer Wegovy?
Wegovy is administered as a once-weekly subcutaneous injection [1]. The injection can be given in the abdomen, thigh, or upper arm [1].
What happens if I miss a dose of Wegovy?
If a dose of Wegovy is missed, it should be taken as soon as possible, provided the next scheduled dose is at least two days away. If the next dose is due within two days, the missed dose should be skipped, and the regular dosing schedule resumed [1].
What is the difference between Wegovy and other weight loss medications?
Wegovy is a GLP-1 receptor agonist that works by affecting appetite and food intake. Other weight loss medications may work through different mechanisms, such as reducing fat absorption or suppressing appetite via different pathways [1].
Are there any contraindications for Wegovy?
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1].
How is Wegovy prescribed and dispensed?
Wegovy is a prescription medication and requires a doctor's order for dispensing. The NDC 00169 is the unique identifier used for this product within the pharmaceutical supply chain [1].
Where can I find more information about Wegovy?
Detailed information about Wegovy, including its uses, side effects, and risks, can be found through healthcare providers and official drug information resources [1].
What are the expected outcomes for patients on Wegovy?
Clinical trials have demonstrated significant weight loss in individuals treated with Wegovy compared to placebo [1]. The specific outcomes can vary based on individual factors and adherence to treatment [1].
Sources:
[1] https://www.drugpatentwatch.com/